Developer docs
API playgroundTry for free, no card

Search company profiles

Spruce Biosciences

Full company profile

uuid0000rrd

Namestring
Spruce Biosciences
Legal namestring
Spruce Biosciences, Inc.
Company typeenum
Public
Founded yearint
2016
Descriptiontext

Spruce Biosciences is a late-stage biopharmaceutical company developing therapies for rare diseases affecting the endocrine and central nervous systems. The company's core asset is tralesinidase alfa enzyme replacement therapy (TA-ERT), an enzyme replacement therapy acquired from BioMarin Pharmaceutical in April 2025 that targets Sanfilippo Syndrome Type B (MPS IIIB), a fatal ultra-rare pediatric neurodegenerative lysosomal storage disorder affecting fewer than one in 200,000 people in the United States with no currently approved disease-modifying therapies. TA-ERT has demonstrated rapid and durable normalization of cerebrospinal fluid heparan sulfate levels and stabilization of cognitive function, communication skills, motor function, and cortical gray matter volume across 22 patients treated for six years with approximately 6,000 doses, and has received FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations with FDA-confirmed potential for accelerated approval via the CSF HS-NRE surrogate endpoint.

The company's secondary pipeline includes tildacerfont (a CRF1 receptor antagonist for congenital adrenal hyperplasia, with its Japan partnership with Kaken Pharmaceutical terminated March 31, 2026) and SPR202 (an anti-CRH monoclonal antibody in collaboration with Harbour BioMed). Spruce Biosciences is publicly traded on NASDAQ under ticker SPRB and operates as a pre-revenue clinical-stage company preparing for BLA submission in Q4 2026 and potential U.S. commercial launch in late 2026 to mid-2027. The company is building a specialty pharmaceutical commercial organization targeting academic medical centers, specialty pharmacies, and rare disease treatment centers, with H.C. Wainwright projecting potential annual pricing of approximately $800,000 per patient and peak U.S. sales exceeding $150 million.

Spruce Biosciences is funded through a combination of private placements ($53.6M in 2023, $50M in 2025), a $50M venture debt facility with Avenue Capital (January 2026, $15M initially drawn), and a $60M underwritten public offering in April 2026, with cash runway projected into 2H 2027. The company reported a $39M net loss for FY2025 and $12.3M net loss for Q1 2026. As of the April 2026 offering, market capitalization was approximately $96.67M with 91.71% institutional ownership including Carlyle Group, Ikarian Capital, and Wellington Management Group.

Short descriptiontext

Spruce Biosciences is a late-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B, an ultra-rare pediatric neurodegenerative disorder with no approved disease-modifying treatments. The company is preparing for a Q4 2026 BLA submission targeting mid-2027 accelerated FDA approval.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, enzyme replacement therapy, biopharmaceutical development, lysosomal storage disorders, endocrine disorder treatments
Industry3 codes
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Rare Disease Biopharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Spruce Biosciences expects to generate revenue through the sale of its approved therapies, primarily tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B, with anticipated potential annual pricing of approximately $800,000 per patient and projected peak U.S. sales exceeding $150 million. The company is preparing for a potential US commercial launch in late 2026 following BLA approval.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details1 tier
1TA-ERT therapy pricing estimated at ~$800,000 per patient annually
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Analyst projection from H.C. Wainwright estimates annual pricing of approximately $800,000 per patient, based on comparable ultra-rare pediatric disease therapies.

investing.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare diseases targeting the endocrine and neurological systems. Its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal pediatric neurodegenerative disorder, with a BLA submission planned for Q4 2026. Additional pipeline assets include tildacerfont for congenital adrenal hyperplasia (CAH) and SPR202, an anti-CRH monoclonal antibody developed in collaboration with Harbour BioMed.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Rapid and durable normalization of cerebral spinal fluid heparan sulfate levels over 6 years of treatment with approximately 6,000 doses
+4 more records
Product overview1 text field

Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare diseases, primarily focusing on neurological and endocrine disorders with significant unmet medical need. The company's core product portfolio consists of three therapeutic candidates: TA-ERT (tralesinidase alfa enzyme replacement therapy), an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB); Tildacerfont, a CRF1 receptor antagonist for rare endocrine disorders including congenital adrenal hyperplasia; and SPR202, an anti-CRH monoclonal antibody. The company is preparing for a potential Biologics License Application submission for TA-ERT in Q4 2026 with anticipated FDA accelerated approval in mid-2027.

Product and service3 records
1TA-ERT (Tralesinidase Alfa Enzyme Replacement Therapy)
CategoryRare Disease Enzyme Replacement Therapy
Description

Enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal pediatric neurodegenerative lysosomal storage disorder. The therapy normalizes cerebrospinal fluid heparan sulfate levels and has demonstrated rapid and durable biomarker normalization and stabilization of cognitive function, communication skills, motor function, and cortical gray matter volume over six years of treatment across 22 patients and approximately 6,000 doses. TA-ERT has received FDA Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation.

2Tildacerfont
CategoryRare Endocrine Disorder Therapeutics
Description

CRF1 receptor antagonist product candidate for the treatment of congenital adrenal hyperplasia (CAH) and other rare endocrine disorders. Originally the company's lead asset and funded by a $53.6M private placement in February 2023 with clinical trial results expected in late 2023, 2024, and 2025.

3SPR202
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1Kaken Pharmaceutical
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Spruce Biosciences and Kaken Pharmaceutical had a collaboration and license agreement for the development, manufacture, and commercialization of tildacerfont for congenital adrenal hyperplasia (CAH) in Japan. The agreement, including initial payments and milestone targets, was mutually terminated effective March 31, 2026 following a comprehensive review. All licenses and rights granted to Kaken ceased, with no future milestone payments or royalties to Spruce.

investing.com
2Harbour BioMed (HBM Holdings)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Harbour BioMed exercised a warrant to acquire common stock in Spruce Biosciences, resulting in approximately 3.8% ownership of total outstanding shares and 3.1% of fully diluted shares. The warrant originated from a license and collaboration agreement between HBM Alpha Therapeutics (incubated by Harbour BioMed) and Spruce, aimed at advancing SPR202, an anti-corticotropin-releasing hormone monoclonal antibody for disorders including congenital adrenal hyperplasia. This transaction transformed the relationship from a traditional licensor-licensee arrangement into a more aligned strategic partnership.

prnewswire.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioMarin originally developed tralesinidase alfa and sold it to Spruce in April 2025. BioMarin remains the most directly comparable rare-disease ERT company (Naglazyme, Vimizim, Aldurazyme co-developer), sharing the same MPS patient advocacy and specialist channel.

TypeDirect peer
Description

Ultragenyx markets multiple enzyme and biologic replacement therapies for ultra-rare diseases (Crysvita, Mepsevii, Dojolvi). Comparable business model focused on small patient populations, premium pricing, and rare-disease commercial infrastructure.

TypeBroad incumbent
Description

Genzyme pioneered lysosomal storage disorder ERTs (Cerezyme, Fabrazyme, Aldurazyme). Sanofi's rare-disease franchise provides an established benchmark for TA-ERT's commercial trajectory and pricing benchmarks in MPS/lysosomal disorders.

TypeBroad incumbent
Description

Through the Shire acquisition, Takeda markets Replagal, Elaprase, and VPRIV (ERTs for Fabry, Hunter, and Gaucher diseases). Directly comparable commercial infrastructure in lysosomal storage disorder specialty channels.

TypeBroad incumbent
Description

Alexion is the archetype ultra-rare disease commercial organization; several of Spruce's newly hired commercial leaders (Brian Walls, Darren Johnson) previously launched products at Alexion. Comparable patient identification and specialty distribution expertise.

TypeEmerging player
Description

Denali is developing enzyme replacement therapies and small molecules for lysosomal storage diseases and neurodegeneration, including MPS programs. Overlapping therapeutic targets and biomarker-driven development approach.

TypeEmerging player
Description

REGENXBIO is advancing AAV-based gene therapies for MPS I (Hurler syndrome) and MPS II, representing the principal long-term competitive threat to chronic ERT administration in the MPS space.

TypeEmerging player
Description

BridgeBio develops therapies for genetic diseases with high unmet need, including rare endocrine and CNS disorders. Comparable small-cap, multi-asset rare-disease biotech profile and similar reliance on accelerated approval pathways.

TypeEmerging player
Description

Orchard focuses on gene therapies for rare pediatric metabolic and neurodegenerative diseases, including MPS disorders. Represents an emerging modality that could compete with chronic ERTs like TA-ERT.

TypeOthers
Description

Moderna's mRNA platform is being explored for in vivo enzyme expression in rare metabolic disorders, representing an adjacent modality that could eventually substitute for ERTs in diseases like MPS IIIB.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Spruce Biosciences

Rare Disease Biopharmaceuticalssprucebiosciences.com

Spruce Biosciences is a late-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B, an ultra-rare pediatric neurodegenerative disorder with no approved disease-modifying treatments. The company is preparing for a Q4 2026 BLA submission targeting mid-2027 accelerated FDA approval.

What Spruce Biosciences does

Spruce Biosciences is a late-stage biopharmaceutical company developing therapies for rare diseases affecting the endocrine and central nervous systems. The company's core asset is tralesinidase alfa enzyme replacement therapy (TA-ERT), an enzyme replacement therapy acquired from BioMarin Pharmaceutical in April 2025 that targets Sanfilippo Syndrome Type B (MPS IIIB), a fatal ultra-rare pediatric neurodegenerative lysosomal storage disorder affecting fewer than one in 200,000 people in the United States with no currently approved disease-modifying therapies. TA-ERT has demonstrated rapid and durable normalization of cerebrospinal fluid heparan sulfate levels and stabilization of cognitive function, communication skills, motor function, and cortical gray matter volume across 22 patients treated for six years with approximately 6,000 doses, and has received FDA Breakthrough Therapy, Rare Pediatric Disease, Fast Track, and Orphan Drug designations with FDA-confirmed potential for accelerated approval via the CSF HS-NRE surrogate endpoint.

The company's secondary pipeline includes tildacerfont (a CRF1 receptor antagonist for congenital adrenal hyperplasia, with its Japan partnership with Kaken Pharmaceutical terminated March 31, 2026) and SPR202 (an anti-CRH monoclonal antibody in collaboration with Harbour BioMed). Spruce Biosciences is publicly traded on NASDAQ under ticker SPRB and operates as a pre-revenue clinical-stage company preparing for BLA submission in Q4 2026 and potential U.S. commercial launch in late 2026 to mid-2027. The company is building a specialty pharmaceutical commercial organization targeting academic medical centers, specialty pharmacies, and rare disease treatment centers, with H.C. Wainwright projecting potential annual pricing of approximately $800,000 per patient and peak U.S. sales exceeding $150 million.

Spruce Biosciences is funded through a combination of private placements ($53.6M in 2023, $50M in 2025), a $50M venture debt facility with Avenue Capital (January 2026, $15M initially drawn), and a $60M underwritten public offering in April 2026, with cash runway projected into 2H 2027. The company reported a $39M net loss for FY2025 and $12.3M net loss for Q1 2026. As of the April 2026 offering, market capitalization was approximately $96.67M with 91.71% institutional ownership including Carlyle Group, Ikarian Capital, and Wellington Management Group.

Spruce Biosciences firmographics

Firmographics
Name
Spruce Biosciences
Legal name
Spruce Biosciences, Inc.
Website
https://sprucebiosciences.com
Company type
Public
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Spruce Biosciences is a late-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for Sanfilippo Syndrome Type B, an ultra-rare pediatric neurodegenerative disorder with no approved disease-modifying treatments. The company is preparing for a Q4 2026 BLA submission targeting mid-2027 accelerated FDA approval.
Ownership category
akta.pro rank

Spruce Biosciences industry classification

Industry
Product category
Rare Disease Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAB
Enzyme Replacement & Metabolic Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIAIAN
Rare Pediatric & Congenital Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals

Keywords

  • Rare disease therapeutics
  • Enzyme replacement therapy
  • Biopharmaceutical development
  • Lysosomal storage disorders
  • Endocrine disorder treatments

Where Spruce Biosciences is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Markets served

Spruce Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Spruce Biosciences expects to generate revenue through the sale of its approved therapies, primarily tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B, with anticipated potential annual pricing of approximately $800,000 per patient and projected peak U.S. sales exceeding $150 million. The company is preparing for a potential US commercial launch in late 2026 following BLA approval.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractTA-ERT therapy pricing estimated at ~$800,000 per patient annually

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Spruce Biosciences product offering

Product offering

Core offering

Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare diseases targeting the endocrine and neurological systems. Its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal pediatric neurodegenerative disorder, with a BLA submission planned for Q4 2026. Additional pipeline assets include tildacerfont for congenital adrenal hyperplasia (CAH) and SPR202, an anti-CRH monoclonal antibody developed in collaboration with Harbour BioMed.

Product overview

Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare diseases, primarily focusing on neurological and endocrine disorders with significant unmet medical need. The company's core product portfolio consists of three therapeutic candidates: TA-ERT (tralesinidase alfa enzyme replacement therapy), an enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB); Tildacerfont, a CRF1 receptor antagonist for rare endocrine disorders including congenital adrenal hyperplasia; and SPR202, an anti-CRH monoclonal antibody. The company is preparing for a potential Biologics License Application submission for TA-ERT in Q4 2026 with anticipated FDA accelerated approval in mid-2027.

Differentiator

Problem solved

Functional benefit

Products and services

  • TA-ERT (Tralesinidase Alfa Enzyme Replacement Therapy) Enzyme replacement therapy for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal pediatric neurodegenerative lysosomal storage disorder. The therapy normalizes cerebrospinal fluid heparan sulfate levels and has demonstrated rapid and durable biomarker normalization and stabilization of cognitive function, communication skills, motor function, and cortical gray matter volume over six years of treatment across 22 patients and approximately 6,000 doses. TA-ERT has received FDA Breakthrough Therapy Designation, Rare Pediatric Disease Designation, Fast Track Designation, and Orphan Drug Designation.
  • Tildacerfont CRF1 receptor antagonist product candidate for the treatment of congenital adrenal hyperplasia (CAH) and other rare endocrine disorders. Originally the company's lead asset and funded by a $53.6M private placement in February 2023 with clinical trial results expected in late 2023, 2024, and 2025.
  • SPR202

Quantifiable outcome

  • Rapid and durable normalization of cerebral spinal fluid heparan sulfate levels over 6 years of treatment with approximately 6,000 doses
  • +4 more outcomes

Companies that use Spruce Biosciences

Customer profile

Segments2 records

Ideal customer profiles2 records

Spruce Biosciences technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Spruce Biosciences partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor and core.

  • Kaken PharmaceuticalminorStrategic or Co-development Partner · 31 March 2026Spruce Biosciences and Kaken Pharmaceutical had a collaboration and license agreement for the development, manufacture, and commercialization of tildacerfont for congenital adrenal hyperplasia (CAH) in Japan. The agreement, including initial payments and milestone targets, was mutually terminated effective March 31, 2026 following a comprehensive review. All licenses and rights granted to Kaken ceased, with no future milestone payments or royalties to Spruce.
  • Harbour BioMed (HBM Holdings)coreStrategic or Co-development PartnerHarbour BioMed exercised a warrant to acquire common stock in Spruce Biosciences, resulting in approximately 3.8% ownership of total outstanding shares and 3.1% of fully diluted shares. The warrant originated from a license and collaboration agreement between HBM Alpha Therapeutics (incubated by Harbour BioMed) and Spruce, aimed at advancing SPR202, an anti-corticotropin-releasing hormone monoclonal antibody for disorders including congenital adrenal hyperplasia. This transaction transformed the relationship from a traditional licensor-licensee arrangement into a more aligned strategic partnership.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Spruce Biosciences competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: BioMarin originally developed tralesinidase alfa and sold it to Spruce in April 2025. BioMarin remains the most directly comparable rare-disease ERT company (Naglazyme, Vimizim, Aldurazyme co-developer), sharing the same MPS patient advocacy and specialist channel.
  • Ultragenyx Pharmaceutical: Ultragenyx markets multiple enzyme and biologic replacement therapies for ultra-rare diseases (Crysvita, Mepsevii, Dojolvi). Comparable business model focused on small patient populations, premium pricing, and rare-disease commercial infrastructure.

Broad incumbents

  • Sanofi (Genzyme): Genzyme pioneered lysosomal storage disorder ERTs (Cerezyme, Fabrazyme, Aldurazyme). Sanofi's rare-disease franchise provides an established benchmark for TA-ERT's commercial trajectory and pricing benchmarks in MPS/lysosomal disorders.
  • Takeda Pharmaceutical: Through the Shire acquisition, Takeda markets Replagal, Elaprase, and VPRIV (ERTs for Fabry, Hunter, and Gaucher diseases). Directly comparable commercial infrastructure in lysosomal storage disorder specialty channels.
  • Alexion Pharmaceuticals (AstraZeneca Rare Disease): Alexion is the archetype ultra-rare disease commercial organization; several of Spruce's newly hired commercial leaders (Brian Walls, Darren Johnson) previously launched products at Alexion. Comparable patient identification and specialty distribution expertise.

Emerging players

  • Denali Therapeutics: Denali is developing enzyme replacement therapies and small molecules for lysosomal storage diseases and neurodegeneration, including MPS programs. Overlapping therapeutic targets and biomarker-driven development approach.
  • REGENXBIO: REGENXBIO is advancing AAV-based gene therapies for MPS I (Hurler syndrome) and MPS II, representing the principal long-term competitive threat to chronic ERT administration in the MPS space.
  • BridgeBio Pharma: BridgeBio develops therapies for genetic diseases with high unmet need, including rare endocrine and CNS disorders. Comparable small-cap, multi-asset rare-disease biotech profile and similar reliance on accelerated approval pathways.
  • Orchard Therapeutics: Orchard focuses on gene therapies for rare pediatric metabolic and neurodegenerative diseases, including MPS disorders. Represents an emerging modality that could compete with chronic ERTs like TA-ERT.

Others

  • Moderna: Moderna's mRNA platform is being explored for in vivo enzyme expression in rare metabolic disorders, representing an adjacent modality that could eventually substitute for ERTs in diseases like MPS IIIB.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Spruce Biosciences social profiles

Digital presence

Spruce Biosciences compliance and trust

Trust signal

Compliance4 records

Spruce Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Spruce Biosciences leadership team

Management profile

Number of profiles

Profiles15 records

Spruce Biosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Spruce Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spruce Biosciences

What does Spruce Biosciences do?

Spruce Biosciences is a late-stage biopharmaceutical company developing novel therapies for rare diseases targeting the endocrine and neurological systems. Its lead candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), is being developed for Sanfilippo Syndrome Type B (MPS IIIB), an ultra-rare fatal pediatric neurodegenerative disorder, with a BLA submission planned for Q4 2026. Additional pipeline assets include tildacerfont for congenital adrenal hyperplasia (CAH) and SPR202, an anti-CRH monoclonal antibody developed in collaboration with Harbour BioMed.

Is Spruce Biosciences a public or private company?

Spruce Biosciences is a public company. It is classified as public and is currently operating.

When was Spruce Biosciences founded?

Spruce Biosciences was founded in 2016. It employs 11 to 50 people.

Where is Spruce Biosciences based?

Spruce Biosciences is headquartered in South San Francisco, United States, in the North America region.

How does Spruce Biosciences make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are Spruce Biosciences's main competitors?

Direct peers on record are BioMarin Pharmaceutical and Ultragenyx Pharmaceutical. Broad incumbents are Sanofi (Genzyme), Takeda Pharmaceutical and Alexion Pharmaceuticals (AstraZeneca Rare Disease). Emerging players are Denali Therapeutics, REGENXBIO, BridgeBio Pharma and Orchard Therapeutics. Moderna is listed as an others.

Does Spruce Biosciences have an API?

No public API is recorded for Spruce Biosciences.

What industry is Spruce Biosciences in?

Spruce Biosciences's product category is Rare Disease Biopharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies, with a secondary code of HLAIAIAB, Enzyme Replacement & Metabolic Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooHarbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone CompanySpruce Biosciences separated its CRHX-101 program into Adrenyx Biosciences, a wholly-owned subsidiary focused on endocrinology, expected to list on Nasdaq in H1 2027. Adrenyx secured US$5 million under a convertible note with potential for up to US$10 million, plus a private placement up to US$50 million. Harbour BioMed expects to hold equity in both Spruce and Adrenyx.PR Newswire APACHarbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone CompanySpruce Biosciences separated its CRHX-101 program into Adrenyx Biosciences, a wholly-owned subsidiary focused on endocrinology, expected to list on Nasdaq in the first half of 2027. Adrenyx secured US$5 million under a convertible note with potential up to US$10 million, and a private placement of up to US$50 million. CRHX-101 targets corticotropin-releasing hormone for congenital adrenal hyperplasia.PR NewswireHarbour BioMed's Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences, Advancing Development of Harbour BioMed-Originated Antibody through a Standalone CompanySpruce Biosciences separated its CRHX-101 program into Adrenyx Biosciences, a wholly-owned subsidiary focused on endocrinology, expected to list on Nasdaq in the first half of 2027. Adrenyx secured US$5 million under a convertible note with potential for up to US$10 million, and a private placement of up to US$50 million. CRHX-101 targets corticotropin-releasing hormone for congenital adrenal hyperplasia.American Banking and Market NewsSpruce Biosciences, Inc. (NASDAQ:SPRB) Stock Has Average Price Target of $158.33Spruce Biosciences received an average "Moderate Buy" rating from 12 analysts, with an average price target of $158.33. The company reported Q4 EPS of -$8.51, missing the -$5.68 consensus, and analysts forecast a full-year loss of -$25.53 per share.Investing.comSpruce Biosciences at Guggenheim healthcare conference: FDA path in focusSpruce Biosciences plans to submit a Biologics License Application for its MPS IIIB drug TA-ERT in December, using the FDA's Accelerated Approval pathway. The FDA has agreed that heparan sulfate is reasonably likely to predict clinical benefit, and the company expects approval in late August or early September 2025. Manufacturing will transfer from Vetter in Germany to Samsung Biologics in South Korea.MarketScreenerSpruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026Spruce Biosciences reported a Q3 net loss of $24.01 million and a nine-month net loss of $52.5 million, both narrower than the prior year. Basic and diluted loss per share from continuing operations were $8.51 and $23.71, respectively, down from $14.58 and $41.25 a year ago.ChartmillSpruce Biosciences (NASDAQ:SPRB) Q3 Loss Widens as TA-ERT BLA Remains on TrackSpruce Biosciences reported Q3 2026 results with no revenue and a loss per share of $8.51, missing the $5.79 estimate. The net loss widened to $24.0 million, and the company reiterated its BLA submission for TA-ERT in MPS IIIB remains on track for December 2026.Stock TitanSpruce Biosciences Separates CRHX-101 Into AdrenyxSpruce Biosciences separated its CRHX-101 program into Adrenyx Biosciences, a new endocrinology subsidiary, and will distribute Adrenyx stock to Spruce shareholders pro rata. The distribution is expected in the first half of 2027 and is taxable for U.S. federal income tax purposes. Adrenyx will advance CRHX-101, a monoclonal antibody targeting corticotropin-releasing hormone in classic congenital adrenal hyperplasia.FierceBiotechSpruce spins out preclinical endocrinology program into newly formed AdrenyxSpruce Biosciences is spinning out its preclinical endocrinology program into a new subsidiary, Adrenyx, with up to $50 million from an unnamed investor. Adrenyx will focus on CRHX-101 for congenital adrenal hyperplasia, while Spruce continues its December filing for TA-ERT. The companies plan to split in the first half of next year.Business Wire BlogSpruce Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceSpruce Biosciences CEO Javier Szwarcberg will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference on November 10, 2026, in Boston. The company's lead product candidate, tralesinidase alfa, is in late-stage development for MPS IIIB and has received multiple FDA designations.